IMC-1121B (ramucirumab)

BIOLOGICAL4 trials

Sponsors

Eli Lilly and Company

Conditions

Carcinoma, Non-Small-Cell LungColorectal CarcinomaMetastatic Malignant MelanomaProstate Cancer

Phase 2

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

CompletedNCT00533702

Eli Lilly and CompanyMetastatic Malignant Melanoma

Start: 2007-11-30End: 2011-05-31Updated: 2014-08-01

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

CompletedNCT00683475

Eli Lilly and CompanyProstate Cancer

Start: 2008-08-31End: 2011-09-30Updated: 2014-10-16

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

CompletedNCT00862784

Eli Lilly and CompanyColorectal Carcinoma

Start: 2009-04-30End: 2011-08-31Updated: 2014-06-17

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT01160744

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung

Start: 2010-09-30End: 2018-04-30Updated: 2019-09-13